Predictive ADMET studies, the challenges and the opportunities

Current Opinion in Chemical Biology

Volumn 8, Issue 4, 2004, Pages 378-386

  Davis, Andrew M ^a   Riley, Robert J ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

absorption, distribution, metabolism elimination and toxicology; ADMET; pharmacokinetic; PK; QSAR; quantitative structure activity relationship; RMSE; root mean square error; volume of distribution; Vss

Indexed keywords

ADSORPTION; COMPUTER MODEL; DATA ANALYSIS; DATA BASE; DISTRIBUTION VOLUME; DRUG RESEARCH; ELIMINATION REACTION; EXPERIMENTAL MODEL; HUMAN; IN VITRO STUDY; IN VIVO STUDY; METABOLISM; NONHUMAN; PREDICTION; REVIEW; STRUCTURE ACTIVITY RELATION; TOXICOLOGY;

ANIMALS; COMPUTER-AIDED DESIGN; DATABASES, FACTUAL; DRUG DESIGN; HUMANS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

ANIMALIA;

EID: 3242885550     PISSN: 13675931     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbpa.2004.06.005     Document Type: Review

References (52)

1. Pintore M., van de Waterbeemd H., Piclin N., Chretien J.R. Prediction of oral bioavailability by adaptive fuzzy partitioning. Eur J Med Chem. 38:2003;427-431
2. Yoshida F., Topliss J.G. QSAR model for drug human oral bioavailability. J Med Chem. 43:2000;2575-2585
3. Turner J.V., Glass B.D., Agatonovic-Kustrin S. Prediction of drug bioavailablity based on molecular structure. Anal Chim Acta. 485:2003;89-102
4. Ekins S., Kim R.B., Leake B.F., Danzig A.H., Schuetz E.G., Lan L.-B., Yasuda K., Shepard R.L., Winter M.A., Schuetz J.D., et al. Three-dimensional quantitative structure-activity relationships of inhibitors of P-glycoprotein. Mol Pharmacol. 61:2002;974-981
5. Lombardo F., Obach R.S., Shalaeva M.Y., Gao F. Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics. J Med Chem. 47:2004;1242-1250
6. Lombardo F., Obach R.S., Shalaeva M.Y., Gao F. Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data. J Med Chem. 45:2002;2867-2876
7. de Groot M.J., Ekins S. Pharmacophore modelling of cytochrome P450. Adv Drug Del Reviews. 54:2002;367-383
8. Afzelius L., Zamora I., Ridderstrom M., Andersson T.B., Karlen A., Masimirembwa C.M. Competitive CYP2C9 inhibitors: enzyme inhibition studies, protein homology modeling, and three-dimensional quantitative structure-activity relationship analysis. Mol Pharmacol. 59:2001;909-919
9. Snyder R., Sangar R., Wang J., Ekins S. 3-Dimensional quantitative structure activity relationship for Cyp2D6 substrates. Quant Struct-Act Relatsh. 21:2002;357-365
10. Susnow R.G., Dixon S.L. Use of robust classification techniques for the prediction of human cytochrome P450 2D6 inhibition. J Chem Inf Comput Sci. 43:2003;1308-1315
11. Lewis D.F. Quantitative structure-activity relationships (QSARs) within the cytochrome P450 system: QSARs describing substrate binding, inhibition and induction of P450s. Inflammopharmacology. 11:2003;43-73
12. Stouch T.R., Kenyon J.R., Johnson S.R., Chen X.-Q., Doweyko A., Li Y. In silico ADME/Tox: why models fail. J Comput Aided Mol Des. 17:2003;83-92 A beautifully honest paper that should be a lesson to all of us, as we have described.
13. Bruneau P. Search for predictive generic model of aqueous solubility using Bayesian neural networks. J Chem Inf Comput Sci. 41:2001;1605-1616 A must-read paper that highlights the importance of structural representation in the training set for optimum predictivity. The implications of this paper to predictive ADMET are enormous.
14. Tetko I. Neural network studies: 4. Introduction to associative neural networks. J Chem Inf Comput Sci. 42:2002;717-728 Associative libraries may extend the longevity of QSAR models to take advantage of new data without having to manually and continually rebuild QSAR models.
15. Tetko I., Tanchuk Y.u. Application of associative neural networks for prediction of lipophilicity in ALOGPS 2.1 Program. J Chem Inf Comput Sci. 42:2002;1136-1145
16. Riley R.J., Parker A.J., Trigg S., Manners C.N. Development if a generalised quantitative physicochemical model of CYP314 inhibition for use in early drug discovery. Pharm Res. 18:2001;652-655 A nice example, we modestly believe, of a small QSAR model highlighting structural features that qualitatively may be more generalisable.
17. Young R.C., Mitchell R.C., Brown T.H., Ganellin C.R., Griffiths R., Jones M., Rana K.K., Saunders D., Smith I., et al. Development of a new physicochemical model for brain penetration and its application to the design of centrally acting H2 receptor histamine antagonists. J Med Chem. 31:1988;656-671
18. Norinder U., Haeberlein M. Computational approaches to the prediction of the blood-brain distribution. Adv Drug Deliv Rev. 54:2002;291-313
19. Lipinski C.A., Lombardo F., Dominy B.W., Feeney P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 46:1997;3-26
20. Veber D.F., Johnson S.R., Cheng H.-Y., Smith B.R., Ward K.W., Kopple K.D. Molecular properties that influence oral availability of drug candidates. J Med Chem. 45:2002;2615-2623
21. Wenlock M.C., Austin R.P., Barton P., Davis A.M., Leeson P.D. A comparison of physicochemical property profiles for development and marketed oral drugs. J Med Chem. 46:2003;1250-1256 This paper has already stimulated a lot of interest, and is being widely cited on the conference circuit. As a survey of development success and failure with respect to physical properties, its conclusions may be far-reaching.
22. Teague S.J., Davis A.M., Leeson P.D., Oprea T.I. The design of leadlike combinatorial libraries. Angew Chem Intl Ed Engl. 38:1999;3743-3748
23. Lewis D.F.V. COMPACT: a structural approach to the modeling of cytochromes P450 and their interactions with xenobiotics. J Chem Technol Biotechnol. 76:2001;237-244
24. Davis A.M., Kleywegt G.J., Teague S.J. Applications and limitations of the use of X-ray crystallographic data in structure-based ligand and drug design. Angew Chem Int Ed Engl. 42:2003;2718-2736
25. Watkins R.E., Wisely G.B., Moore L.B., Collins J.L., Lambert M.H., Williams S.P., Wilson T.M., Kleiwer S.A., Redimbo M.R. The human nuclear xenobiotic receptor PXR: structural determinants of directed promiscuity. Science. 292:2001;2329-2333
26. Petitpas I., Gruene T., Bhattacharya A.A., Curry S. Crystal structures of human serum albumin complexed with monounsaturated and polyunsaturated fatty acids. J Mol Biol. 314:2001;955-960
27. Petitpas I., Bhattacharya A.A., Twine S., East M., Curry S. Crystal structure analysis of warfarin binding to human serum albumin: anatomy of drug site I. J Biol Chem. 276:2001;22804-22809
28. Williams P.A., Cosme J., Sridhar V., Johnson E.F., McRae D.E. Mammalian microsomal cytochrome P450 monooxygenase: structural adaptations for membrane binding and functional diversity. Mol Cell. 5:2000;121-131
29. Williams P.A., Cosme J., Ward A., Angove H.C., Vinkovic D.M., Jhoti H. Crystal structure of human cytochrome P450 2C9 with bound warfarin. Nature. 424:2003;464-468 First human cytochrome P450 X-ray crystal structure.
30. Chiou W.L., Barve A. Linear correlation of the fraction of oral dose absorbed of 64 drugs between humans and rats. Pharm Res. 15:1998;1792-1795
31. Chiou W.L., Jeong H.Y., Chung S.M., Wu T.C. Evaluation of using dog as an animal model to study the fraction of oral dose absorbed of 43 drugs in humans. Pharm Res. 17:2000;135-140
32. Chiou W.L., Buehler P.W. Comparison of oral absorption and bioavailability of drugs between monkey and human. Pharm Res. 19:2002;868-874
33. Hodgson J. ADMET- turning chemicals into drugs. Nat Biotechnol. 19:2001;722-726
34. Theil F.-P., Guentert T.W., Haddad S., Poulin P. Utility of physiologically based pharmacokinetic models to drug development and rational drug discovery candidate selection. Toxicol Lett. 138:2003;29-49 An up-to-date overview and appraisal of an in-vogue approach.
35. Mahmood I., Balian J.D. The pharmacokinetic principles behind scaling from preclinical results to phase I protocols. Clin Pharmacokinet. 36:1999;1-11
36. Wajima T., Fukumura K., Yano Y., Oguma T. Prediction of human clearance from animal data and molecular structural parameters using multivariate regression analysis. J Pharm Sci. 91:2002;2489-2499
37. Lin J.H. Applications and limitations of interspecies scaling and in vitro extrapolation in pharmacokinetics. Drug Metab Dispos. 26:1998;1202-1212
38. Obach R.S., Baxter J.G., Liston T.E., Silber B.M., Jones B.C., MacIntyre F., Rance D.J., Wastall P. The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J Pharmacol Exp Ther. 283:1987;46-58
39. Houston J.B. Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem Pharmacol. 47:1994;1469-1479
40. Houston J.B., Carlile D.J. Prediction of hepatic clearance from microsomes, hepatocytes and liver slices. Drug Metab Rev. 29:1997;891-922
41. Obach R.S. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab Dispos. 27:1999;1350-1359
42. Lau Y.Y., Sapidou E., Cui X., White R.E., Cheng K.C. Development of a novel in vitro model to predict hepatic clearance using fresh, cryopreserved and sandwich-cultured hepatocytes. Drug Metab Dispos. 30:2002;1446-1454
43. Shibata Y., Takahashi H., Ishii Y. A convenient in vitro screening method for predicting in vivo drug metabolic clearance using isolated hepatocytes suspended in serum. Drug Metab Dispos. 28:2000;1518-1523
44. Naritomi Y., Terashita S., Kagayama A., Sugiyama Y. Utility of hepatocytes in predicting drug metabolism: comparison of hepatic intrinsic clearance in rats and humans in vivo and in vitro. Drug Metab Dispos. 31:2003;580-588
45. Naritomi Y., Terashita S., Kimura S., Suzuki A., Kagayama A., Sugiyama Y. Prediction of human hepatic clearance from in vivo animal experiments and in vitro metabolic studies with liver microsomes from animals and humans. Drug Metab Dispos. 29:2001;1316-1324
46. Ito K., Chiba K., Horikawa M., Ishigama M., Mizuno N., Aoki J., Gotoh Y., Iwatsubo T., Kanamitsu S., Kato M., et al. Which concentration of the inhibitor should be used to predict in vivo drug interactions from in vitro data? AAPS PharmSci. 4:2002;1-8 A useful database for clinical drug-drug interactions ascribed to human CYPs.
47. Bonnabry P, Sievering J, Leemann T, Dayer P: Predictive modelling of in vivo drug interaction from in vitro data: from theory to a computer-based workbench and its experimental validation. In Interindividual Variability in Drug Metabolism. Edited by Pacifici GM, Pelkonen O: Taylor & Francis; 2001:240-268.
48. Kanamitsu S.-I., Ito K., Green C.E., Tyson C.A., Shimada N., Sugiyama Y. Prediction of in vivo interaction between triazolam and erythromycin based on in vitro studies using human liver microsomes and recombinant human CYP3A4. Pharm Res. 17:2000;419-426
49. Black D.J., Kunze K.L., Weinkers L.C., Gidal B.E., Seaton T.L., McDonnell N.D., Evans J.S., Bauwens J.E., Trager W.F. Warfarin-fluconazole II. A metabolically based drug interaction: in vivo studies. Drug Metab Disp. 24:1996;422-428
50. Yao C., Kunze K.L., Kharasch E.D., Wang Y., Trager W.F., Ragueneau I., Levy R.H. Fluvoxamine-theophylline interaction: gap between in vitro and in vivo inhibition constants toward cytochrome P4501A2. Clin Pharmacol Ther. 70:2001;415-424
51. Yao C., Kunze K.L., Trager W.F., Kharasch E.D., Levy R.H. Comparison of in vitro and in vivo inhibition potencies of fluvoxamine toward CYP2C19. Drug Metab Dispos. 31:2003;565-571
52. Ubeaud G., Hagenbach J., Vandenschrieck S., Jung L., Koffel J.C. In vitro inhibition of simvastatin metabolism in rat and human liver by naringenin. Life Sci. 65:1999;1403-1412